Westport, CT, Nov. 14, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company has issued its November 2019 Shareholder Letter.
Shareholder Letter highlights include:
- Commercialization plans that include the installation of PURE EP™ Systems at up to 9 centers throughout the U.S. in the first half of 2020
- Updates on Texas Cardiac Arrhythmia Institute’s (TCAI) evaluation of clinical cases
- Further PURE EP™ System installations are scheduled to begin at the University of Pennsylvania in Philadelphia and at Mayo Clinic in Jacksonville before year end
- Clinical trial with the PURE EP™ System to commence in November 2019
- The Company’s subsidiary, NeuroClear Technologies, Inc., raised $3.7 million in initial funding
- New licensing agreement with Mayo Clinic and the opening of a new corporate office in Rochester, MN to support our Mayo collaboration
- Presented first clinical observations at Venice Arrhythmias 2019, a distinguished industry event held every two years in Italy, and at the 14th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy
- Additions of key personnel and a new Board member and updates to our intellectual property portfolio.
To view the Company’s November 2019 Shareholder Letter, please visit our website:https://ir.biosig.com.
About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace (www.biosig.com). Led by a proven management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE EP(tm) System. The technology has been developed to address an unmet need in a large and growing market.
